Radiotherapy uses high-energy rays to destroy the cancer cells, while doing as little harm as possible to normal cells.
- areas on the face (such as near the nose)
- large areas
- cancers that are deep in the skin.
However, radiotherapy is not recommended for young people, as it can cause skin changes which may become more visible over time.
Radiotherapy is occasionally used when a non-melanoma skin cancer has spread to other places. This can include lymph nodes or an organ such as the lungs.
You have the treatment in the hospital radiotherapy department. You may only have a single treatment, but usually several doses are needed. You have these each day over 1 or more weeks. Your doctor will discuss your treatment plan with you.
Radiotherapy treatment affects only a small area of skin and will not make you feel unwell. The treated skin will be red and inflamed for up to a month after treatment. During this time, it will look as though the treatment has made things worse rather than better. This is normal. After a few more weeks, the area will dry up and form a crust or scab. In time, the scab will peel away, leaving healed skin underneath.
At first, this new skin will look pinker than the skin around it. This should gradually fade and the treated area will start to look like the skin around it, although it may be slightly paler. If you have dark skin, you might notice that the area gets darker.
Radiotherapy to areas where hair grows can make the hair fall out in the treated area. Your hair usually grows back in 6 to 12 months, depending on the dose of radiotherapy and how many sessions you have had. Some people find that the hair loss is permanent. You can talk to your clinical oncologist about whether your hair is likely to grow back after treatment.
Radiotherapy for skin cancer does not make you radioactive. This means it is safe for you to be around other people, including children, during your treatment.
We have more detailed information about radiotherapy.
Below is a sample of the sources used in our skin cancer information. If you would like more information about the sources we use, please contact us at email@example.com
Motley et al. British Association of Dermatologists. Management of the patient with primary cutaneous squamous cell carcinoma. 2009.
National Institute for Health and Care Excellence (NICE). NG12: Suspected cancer: recognition and referral. 2015 (updated 2017).
National Institute for Health and Care Excellence (NICE). NG134: Sunlight Exposure: Benefits and Risks. 2016.
National Institute for Health and Care Excellence (NICE). PH32: Skin Cancer Prevention. 2011 (updated 2016).
Scottish Intercollegiate Guidelines Network (SIGN) 140. Management of primary cutaneous squamous cell carcinoma. 2014.
Telfar N et al. Guidelines for the management of basal cell carcinoma. British Journal of Haematology. 2008.
This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Professor James Larkin, Consultant Medical Oncologist.
Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.